<a href="https://www.fiercebiotech.com/biotech/lilly-locks-vague-5-program-rd-pact-chinas-haisco-worth-3b" hreflang="en">Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear</a>
Eli Lilly has entered a five-program research and development agreement with China's Haisco Pharmaceutical Group, potentially worth up to $3 billion, focusing on multiple therapeutic areas, though specific targets remain undisclosed. The deal includes an upfront payment of $87 million and up to $2.97 billion in milestone payments, aligning with Lilly's strategy to expand its portfolio through international collaborations.
For a professional tracking biotech and healthtech investments, Eli Lilly's recent $3 billion R&D partnership with China's Haisco is a significant signal of the increasing trend of cross-border collaborations in drug development. This deal underscores the strategic importance of diversifying pipelines through international partnerships, highlighting potential opportunities for investment in companies that are actively engaging in global collaborations to accelerate innovative therapies across multiple therapeutic areas.